{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tacrolimus%2FSirolimus&page=5", "query": { "intervention": "Tacrolimus/Sirolimus", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 164, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tacrolimus%2FSirolimus&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tacrolimus%2FSirolimus&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T06:07:37.867Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00577278", "title": "A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Versus Host Disease", "Leukemia", "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "indium In 111 ibritumomab tiuxetan", "type": "RADIATION" }, { "name": "yttrium Y 90 ibritumomab tiuxetan", "type": "RADIATION" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 41, "start_date": "2007-10-03", "completion_date": "2023-12-14", "has_results": true, "last_update_posted_date": "2024-02-16", "last_synced_at": "2026-10-02T06:07:37.867Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00577278" }, { "nct_id": "NCT00928018", "title": "Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-hodgkin Lymphoma", "Hodgkin Lymphoma" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "MMF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 139, "start_date": "2009-06", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2019-02-01", "last_synced_at": "2026-10-02T06:07:37.867Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Minneapolis, Minnesota + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00928018" }, { "nct_id": "NCT04989686", "title": "Microsampling Assays for Immunosuppressive Drugs in Children", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Immunosuppression" ], "interventions": [ { "name": "Microsampling", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "17 Years", "sex": "ALL", "summary": "Up to 17 Years" }, "enrollment_count": 66, "start_date": "2023-06-08", "completion_date": "2025-05-01", "has_results": false, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-10-02T06:07:37.867Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04989686" }, { "nct_id": "NCT02891603", "title": "A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Graft Vs Host Disease", "GVHD" ], "interventions": [ { "name": "Pacritinib", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Allogenic hematopoietic cell transplant (alloHCT)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2017-06-08", "completion_date": "2022-04-18", "has_results": true, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-10-02T06:07:37.867Z", "location_count": 2, "location_summary": "Tampa, Florida • Minneapolis, Minnesota", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02891603" }, { "nct_id": "NCT00589563", "title": "Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Graft Versus Host Disease", "Infection", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Precancerous Condition", "Secondary Myelofibrosis", "Small Intestine Cancer" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "total-body irradiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 32, "start_date": "2007-05", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2014-09-10", "last_synced_at": "2026-10-02T06:07:37.867Z", "location_count": 2, "location_summary": "Phoenix, Arizona • Duarte, California", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00589563" }, { "nct_id": "NCT01878786", "title": "A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Delayed Graft Function" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF/MPA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Matthew Cooper", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 25, "start_date": "2013-06", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2019-04-26", "last_synced_at": "2026-10-02T06:07:37.867Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01878786" }, { "nct_id": "NCT00866879", "title": "Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Renal Transplant Rejection" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Demographic Data, Medical History, and Donor Data", "type": "OTHER" }, { "name": "Blood Draws for Control Group", "type": "PROCEDURE" }, { "name": "Blood Draws for Experimental Group", "type": "PROCEDURE" }, { "name": "Donor Blood Draws", "type": "PROCEDURE" }, { "name": "Donor Information", "type": "OTHER" }, { "name": "Kidney Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 275, "start_date": "2007-06", "completion_date": "2019-03", "has_results": true, "last_update_posted_date": "2019-06-28", "last_synced_at": "2026-10-02T06:07:37.867Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00866879" }, { "nct_id": "NCT00999258", "title": "Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Glomerular Filtration Rate", "Chronic Allograft Nephropathy" ], "interventions": [ { "name": "sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Temple University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2009-09", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2009-10-21", "last_synced_at": "2026-10-02T06:07:37.867Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00999258" }, { "nct_id": "NCT00464555", "title": "Strategies to Improve Islet Survival", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Islet transplant", "type": "PROCEDURE" }, { "name": "Antithymocyte globulin", "type": "DRUG" }, { "name": "Basiliximab", "type": "DRUG" }, { "name": "Lisofylline", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 5, "start_date": "2006-12", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2016-04-26", "last_synced_at": "2026-10-02T06:07:37.867Z", "location_count": 2, "location_summary": "Miami, Florida • Chicago, Illinois", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00464555" }, { "nct_id": "NCT01935128", "title": "Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Renal Transplant" ], "interventions": [ { "name": "Arm 1 Everolimus/Reduced dose tacrolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Toledo Health Science Campus", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2013-07-03", "completion_date": "2020-07", "has_results": true, "last_update_posted_date": "2022-05-26", "last_synced_at": "2026-10-02T06:07:37.867Z", "location_count": 1, "location_summary": "Toledo, Ohio", "locations": [ { "city": "Toledo", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01935128" } ] }